Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

Jonathan L. Dumbrill; Calum D. Moulton

doi:10.1016/j.pcd.2017.06.009

Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

Jonathan L. Dumbrill, Calum D. Moulton

Psychological Medicine

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

299 Downloads (Pure)

Abstract

We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.

Original language	English
Journal	Primary Care Diabetes
Early online date	18 Jul 2017
DOIs	https://doi.org/10.1016/j.pcd.2017.06.009
Publication status	E-pub ahead of print - 18 Jul 2017

Keywords

Dementia
Incretin-based therapy
Systematic review

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.pcd.2017.06.009

Effects of incretin-based therapies_DUMBRILL_Publishedonline18July2017_GREEN AAMAccepted author manuscript, 250 KBLicence: CC BY-NC-ND

Cite this

@article{813a570e02524ca0b3c2d1ea8e8bba49,

title = "Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature",

abstract = "We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.",

keywords = "Dementia, Incretin-based therapy, Systematic review",

author = "Dumbrill, {Jonathan L.} and Moulton, {Calum D.}",

year = "2017",

month = jul,

day = "18",

doi = "10.1016/j.pcd.2017.06.009",

language = "English",

journal = "Primary Care Diabetes",

issn = "1751-9918",

publisher = "SB Communications Group",

}

TY - JOUR

T1 - Effects of incretin-based therapies on neurocognitive function in humans

T2 - A systematic review of the literature

AU - Dumbrill, Jonathan L.

AU - Moulton, Calum D.

PY - 2017/7/18

Y1 - 2017/7/18

N2 - We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.

AB - We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.

KW - Dementia

KW - Incretin-based therapy

KW - Systematic review

U2 - 10.1016/j.pcd.2017.06.009

DO - 10.1016/j.pcd.2017.06.009

M3 - Article

SN - 1751-9918

JO - Primary Care Diabetes

JF - Primary Care Diabetes

ER -

Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this